Orforglipron was approved for weight management in April 2026, covered in the oral one is approved now. This trial tested it where most diabetes drugs are actually decided — as the thing added when metformin is no longer enough [1].
The design deserves a moment because the phrase appears constantly and is rarely explained. A non-inferiority trial does not set out to show a drug is better; it sets out to show it is not worse by more than an agreed margin, here 0.3 percentage points of HbA1c. That is a lower bar, chosen when a new drug offers some other advantage — in this case a tablet rather than an injection — and only needs to hold its own on effect.
It did considerably more than hold its own. At week 40, HbA1c fell 1.23, 1.50 and 1.56 percentage points on the 3, 12 and 36 mg doses against 0.81 with dapagliflozin, giving treatment differences of -0.42 (95% CI -0.62 to -0.23), -0.70 (-0.90 to -0.49) and -0.75 (-0.96 and below). A trial built to demonstrate equivalence producing superiority is a stronger signal than a superiority trial succeeding, because nobody designed it to find that.
One design choice makes the result more useful than it might have been. The primary analysis used a treatment-regimen estimand, counting each participant’s data whether or not they stopped the study drug or added another glucose-lowering agent. That measures what happens when someone is put on a drug rather than what happens if they stay on it perfectly, which is the more honest question given how many people discontinue — the figures in the network meta-analysis of nineteen drugs put orforglipron among the highest for stopping because of adverse events.
The trial was open-label, so everyone knew what they were taking. HbA1c is a laboratory measure and difficult to influence directly, but knowing you are on the new drug can change adherence and effort in ways the estimand absorbs rather than removes. That is a smaller concern here than in a trial with subjective endpoints, and it is worth noting alongside the pipeline picture in the ecnoglutide trial.